Restorative treatments of dystrophin expression in Duchenne muscular dystrophy: A systematic review
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Restorative treatments of dystrophin expression in Duchenne muscular dystrophy: A systematic review
Authors
Keywords
-
Journal
Annals of Clinical and Translational Neurology
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2020-08-10
DOI
10.1002/acn3.51149
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effectiveness of pharmacological treatments in Duchenne muscular dystrophy: a protocol for a systematic review and meta-analysis
- (2019) Carlos Pascual Morena et al. BMJ Open
- Improvements in health status and utility associated with ataluren for the treatment of nonsense mutation Duchenne muscular dystrophy
- (2019) Erik Landfeldt et al. MUSCLE & NERVE
- Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study
- (2018) Craig M McDonald et al. LANCET
- Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management
- (2018) David J Birnkrant et al. LANCET NEUROLOGY
- Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management
- (2018) David J Birnkrant et al. LANCET NEUROLOGY
- Eteplirsen treatment for Duchenne muscular dystrophy
- (2018) Jay S. Charleston et al. NEUROLOGY
- A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy
- (2018) Nathalie Goemans et al. NEUROMUSCULAR DISORDERS
- Exon skipping for Duchenne muscular dystrophy: a systematic review and meta-analysis
- (2018) Yuko Shimizu-Motohashi et al. Orphanet Journal of Rare Diseases
- Systemic administration of the antisense oligonucleotide NS-065/NCNP-01 for skipping of exon 53 in patients with Duchenne muscular dystrophy
- (2018) Hirofumi Komaki et al. Science Translational Medicine
- Placebo-controlled Phase 2 Trial of Drisapersen for Duchenne Muscular Dystrophy
- (2018) Craig M. McDonald et al. Annals of Clinical and Translational Neurology
- Off-Label Use of Ataluren in Four Non-ambulatory Patients With Nonsense Mutation Duchenne Muscular Dystrophy: Effects on Cardiac and Pulmonary Function and Muscle Strength
- (2018) Daniel Ebrahimi-Fakhari et al. Frontiers in Pediatrics
- A current approach to heart failure in Duchenne muscular dystrophy
- (2017) Domenico D’Amario et al. HEART
- Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Craig M McDonald et al. LANCET
- FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga
- (2017) Annemieke Aartsma-Rus et al. Nucleic Acid Therapeutics
- Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy
- (2016) Jerry R. Mendell et al. ANNALS OF NEUROLOGY
- Exon skipping therapy for Duchenne muscular dystrophy
- (2015) Ryszard Kole et al. ADVANCED DRUG DELIVERY REVIEWS
- The TREAT-NMD DMD Global Database: Analysis of More than 7,000 Duchenne Muscular Dystrophy Mutations
- (2015) Catherine L. Bladen et al. HUMAN MUTATION
- European Medicines Agency review of ataluren for the treatment of ambulant patients aged 5 years and older with Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene
- (2015) Manuel Haas et al. NEUROMUSCULAR DISORDERS
- Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study
- (2014) Thomas Voit et al. LANCET NEUROLOGY
- Ataluren treatment of patients with nonsense mutation dystrophinopathy
- (2014) Katharine Bushby et al. MUSCLE & NERVE
- A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy
- (2014) Jean K. Mah et al. NEUROMUSCULAR DISORDERS
- Comparative cost of illness analysis and assessment of health care burden of Duchenne and Becker muscular dystrophies in Germany
- (2014) Olivia Schreiber-Katz et al. Orphanet Journal of Rare Diseases
- Eteplirsen for the treatment of Duchenne muscular dystrophy
- (2013) Jerry R. Mendell et al. ANNALS OF NEUROLOGY
- Pharmacokinetics and safety of single doses of drisapersen in non-ambulant subjects with Duchenne muscular dystrophy: Results of a double-blind randomized clinical trial
- (2013) Kevin M. Flanigan et al. NEUROMUSCULAR DISORDERS
- Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study
- (2011) Sebahattin Cirak et al. LANCET
- Systemic Administration of PRO051 in Duchenne's Muscular Dystrophy
- (2011) Nathalie M. Goemans et al. NEW ENGLAND JOURNAL OF MEDICINE
- Exon-skipping therapy for Duchenne muscular dystrophy
- (2009) Akinori Nakamura et al. NEUROPATHOLOGY
- The GRADE System for Rating Clinical Guidelines
- (2009) Brian P. Kavanagh PLOS MEDICINE
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2009) David Moher et al. PLOS MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation